60 DEGREES PHARMA INC-28(NASDAQ:SXTPW) stock News

SXTPW Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: ACCESS Newswire - Mentions: SXTP

Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22

a month ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

2 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

3 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

3 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

3 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

3 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

3 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

4 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

4 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

5 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

6 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

6 months ago - By: Yahoo Finance - Mentions: SXTP

Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?

6 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

6 months ago - By: Yahoo Finance - Mentions: TTWO TQQQ SOXL EXPE ...

Why Take-Two Interactive Stock Surged Today

6 months ago - By: Yahoo Finance - Mentions: EXPE JPM HAS IGC ...

Expedia Group, Inc. (EXPE): Among the Best Cruise Stocks to Buy According to Hedge Funds

6 months ago - By: Yahoo Finance - Mentions: HAS VZ DIS EXPE ...

Hasbro, Inc. (HAS): A Bull Case Theory

6 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

6 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals Announces 2024 Annual Results

8 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

8 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

8 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

8 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

8 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

8 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

9 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

10 months ago - By: Sixty Degrees Pharmaceuticals - Mentions: SXTP